Lepu Bio Announces $127 Million Series A Financing Led by Shiyu Capital

VCBeat (WeChat ID: vcbeat) has learned that on July 1, Lepu Biopharma Co., Ltd. (hereinafter referred to as “Lepu Biopharma”) announced the completion of its Series A financing round amounting to RMB 900 million. The round was led by Shiyu Capital, with participation from Suzhou Min Tou, Kaiyuan Guochuang, Suzhou Xinrui, and Lecheng Medical. Listed company Lepu Medical also followed up with additional investment.

This round of financing will be used to advance clinical trials for LEPU BIOPHARMA’s core projects, construct macromolecule production lines, introduce product pipeline assets, and build its talent team.

LEPU BIOPHARMA, established in 2018, focuses on tumor immunotherapy and has built a comprehensive industrial platform encompassing target discovery, drug development, clinical development, and manufacturing. It owns nine subsidiaries, including Houde Aoke, Hanzhong Biopharma, Shanghai Meiyake, and Shanghai Hangjia Incubator. Its core products, including PD-1, PD-L1, oncolytic viruses, and multiple antibody-drug conjugate (ADC) candidates, have entered various stages of Phase I–III clinical trials with outstanding results. The company plans to pursue combination therapies involving multiple products in the future.

Pu Zhongjie, Chairman of LEPU BIOPHARMA, stated: “We sincerely thank investors for their trust and investment in LEPU BIOPHARMA. Focusing on tumor immunotherapy, we leverage differentiated clinical strategies and our years-accumulated capability in integrating industrial resources to rapidly advance product clinical trials and production line construction. By addressing significant unmet clinical needs in the field of oncology, we aim to achieve leapfrog and sustainable development for LEPU BIOPHARMA, positioning it as an advanced tumor immunotherapy company rooted in China and serving the world.”

Yang Hongbing, Founding Partner and Chairman of Shiyu Capital, stated: “LEPU BIOPHARMA is focused on tumor immunotherapy, a revolutionary treatment modality that has emerged in recent years. Despite being established for just over a year, LEPU BIOPHARMA has efficiently built a robust product pipeline centered on PD-1 and PD-L1 monoclonal antibodies, complemented by multiple ADCs, oncolytic viruses, and bispecific antibodies. With strong resource integration capabilities and distinct advantages in late-stage clinical development, manufacturing, sales, and commercialization, the company is poised to become a highly competitive biopharmaceutical enterprise in the field of tumor immunotherapy.”